Literature DB >> 32466877

External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study.

Romain Diamand1, Marco Oderda2, Simone Albisinni3, Alexandre Fourcade4, Georges Fournier4, Daniel Benamran5, Christophe Iselin5, Gaelle Fiard6, Jean-Luc Descotes6, Grégoire Assenmacher7, Ilyas Svistakov7, Alexandre Peltier7, Giuseppe Simone8, Giacomo Di Cosmo9, Jean-Baptiste Roche9, Jean-Louis Bonnal10, Julien Van Damme11, Maxime Rossi12, Eric Mandron12, Paolo Gontero2, Thierry Roumeguère3.   

Abstract

OBJECTIVE: To validate a nomogram predicting lymph node invasion (LNI) in prostate cancer patients undergoing radical prostatectomy taking into consideration multiparametric-magnetic resonance imaging (mp-MRI) parameters and targeted biopsies in a western European cohort. PATIENTS AND METHODS: A total of 473 men diagnosed by targeted biopsies, using software-based MRI-ultrasound image fusion system, and operated by radical prostatectomy with extended pelvic lymph node dissection across 11 Europeans centers between 2012 and 2019 were identified. Area under the curve of the receiver operator characteristic curve, calibration plot and decision curve analysis were used to evaluated the performance of the model.
RESULTS: Overall, 56 (11.8%) patients had LNI on final pathologic examination with a median (IQR) of 13 (9-18) resected nodes. Significant differences (all P < 0.05) were found between patients with and without LNI in terms of preoperative PSA, clinical stage at DRE and mp-MRI, maximum diameter of the index lesion, PI-RADS score, Grade Group on systematic and targeted biopsies, total number of dissected lymph nodes, final pathologic staging and Grade Group. External validation of the prediction model showed a good accuracy with an area under the curve calculated as 0.8 (CI 95% 0.75-0.86). Graphic analysis of calibration plot and decision curve analysis showed a slight underestimation for predictive probability for LNI between 3% and 22% and a high net benefit. A cut-off at 7% was associated with a risk of missing LNI in 2.6%, avoiding unnecessary surgeries in 55.9%.
CONCLUSIONS: We report an external validation of the nomogram predicting LNI in patients treated with extended pelvic lymph node dissection in a western European cohort and a cut-off at 7% seems appropriate.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymph node invasion; MRI; Nomogram; Prostate cancer; Targeted biopsy

Year:  2020        PMID: 32466877     DOI: 10.1016/j.urolonc.2020.04.011

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  3 in total

1.  External Validation and Comparison of Two Nomograms Predicting the Probability of Lymph Node Involvement in Patients subjected to Robot-Assisted Radical Prostatectomy and Concomitant Lymph Node Dissection: A Single Tertiary Center Experience in the MRI-Era.

Authors:  Nicola Frego; Marco Paciotti; Nicolò Maria Buffi; Davide Maffei; Roberto Contieri; Pier Paolo Avolio; Vittorio Fasulo; Alessandro Uleri; Massimo Lazzeri; Rodolfo Hurle; Alberto Saita; Giorgio Ferruccio Guazzoni; Paolo Casale; Giovanni Lughezzani
Journal:  Front Surg       Date:  2022-02-25

2.  External Validation of the Briganti Nomogram to Predict Lymph Node Invasion in Prostate Cancer-Setting a New Threshold Value.

Authors:  Bartosz Małkiewicz; Kuba Ptaszkowski; Klaudia Knecht; Adam Gurwin; Karol Wilk; Paweł Kiełb; Krzysztof Dudek; Romuald Zdrojowy
Journal:  Life (Basel)       Date:  2021-05-25

3.  External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer.

Authors:  Eri Fukagawa; Shinya Yamamoto; Sachiko Ohde; Kasumi Kaneko Yoshitomi; Kosuke Hamada; Yusuke Yoneoka; Motohiro Fujiwara; Ryo Fujiwara; Tomohiko Oguchi; Yoshinobu Komai; Noboru Numao; Takeshi Yuasa; Iwao Fukui; Junji Yonese
Journal:  Int J Clin Oncol       Date:  2021-06-12       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.